Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

被引：13

作者：

Karrar, Omer ^{[1
]}

Abdelmagid, Maymona ^{[1
]}

Rana, Masooma ^{[1
]}

Iftikhar, Moazah ^{[1
]}

McCullough, Kristen ^{[1
]}

Al-Kali, Aref ^{[1
]}

Alkhateeb, Hassan B. ^{[1
]}

Begna, Kebede H. ^{[1
]}

Elliott, Michelle A. ^{[1
]}

Mangaonkar, Abhishek ^{[1
]}

Saliba, Antoine ^{[1
]}

Torghabeh, Mehrdad Hefazi ^{[1
]}

Litzow, Mark R. ^{[1
]}

Hogan, William ^{[1
]}

Shah, Mithun ^{[1
]}

Patnaik, Mrinal M. ^{[1
]}

Pardanani, Animesh ^{[1
]}

Badar, Talha ^{[2
]}

Murthy, Hemant ^{[2
]}

Foran, James ^{[2
]}

Palmer, Jeanne ^{[3
]}

Sproat, Lisa ^{[3
]}

Khera, Nandita ^{[3
]}

Yi, Cecilia Arana ^{[3
]}

Tefferi, Ayalew ^{[1
]}

Gangat, Naseema ^{[1
,4
]}

机构：

[1] Mayo Clin, Dept Med, Div Hematol, Rochester, MN USA

[2] Div Hematol & Oncol, Div Hematol, Jacksonville, FL USA

[3] Mayo Clin, Div Hematol, Scottsdale, AZ USA

[4] Mayo Clin, Dept Med, Div Hematol, 200 First St SW, Rochester, MN 55905 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 02期

关键词：

D O I：

10.1002/ajh.27180

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).image

引用

页码：E63 / E66

页数：4

共 45 条

[1] VENETOCLAX IN COMBINATION WITH AZACITIDINE IS COST-EFFECTIVE VS. AZA FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A CANADIAN PERSPECTIVE
Guinan, K.
Mathurin, K.
Au, Y.
Schuh, A. C.
Bui, C. N.
Chai, X.
Lachaine, J.
VALUE IN HEALTH, 2022, 25 (07) : S344 - S344
[2] Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent plus Venetoclax Vs. High Intensity Regimens
Li Krackeler, Margaret
Moskoff, Benjamin
Othman, Tamer
Azenkot, Tali
Beechinor, Ryan J.
Rosenberg, Aaron S.
Esteghamat, Naseem S.
Hoeg, Rasmus T.
Tuscano, Joseph M.
Jonas, Brian A.
BLOOD, 2022, 140 : 8926 - 8928
[3] Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Gangat, Naseema
Karrar, Omer
Iftikhar, Moazah
Mccullough, Kristen
Johnson, Isla M.
Abdelmagid, Maymona
Abdallah, Mostafa
Al-Kali, Aref
Alkhateeb, Hassan B.
Begna, Kebede H.
Mangaonkar, Abhishek
Saliba, Antoine N.
Torghabeh, Mehrdad Hefazi
Litzow, Mark R.
Hogan, William
Shah, Mithun
Patnaik, Mrinal M.
Pardanani, Animesh
Badar, Talha
Murthy, Hemant
Foran, James
Palmer, Jeanne
Sproat, Lisa
Khera, Nandita
Yi, Cecilia Arana
Tefferi, Ayalew
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (02) : 193 - 202
[4] Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Asghari, Hannah
Lee, Dasom
Deutsch, Yehuda E.
Chan, Onyee
Al Ali, Najla
Boisclair, Stephanie
Terrell, Constance
Padron, Eric
Kuykendall, Andrew T.
List, Alan F.
Fernandez, Hugo F.
Lancet, Jeffrey E.
Sallman, David A.
Komrokji, Rami S.
Sweet, Kendra L.
Talati, Chetasi
BLOOD, 2019, 134
[5] Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience
Vachhani, Pankit
Al Yacoub, Raed
Miller, Austin
Cronin, Tara
Ontiveros, Evelena
Thompson, James
Griffiths, Elizabeth
Wang, Eunice
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S288 - S289
[6] Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience
Vachhani, Pankit
Al Yacoub, Raed
Miller, Austin
Zhang, Fan
Cronin, Tara L.
Ontiveros, Evelena P.
Thompson, James E.
Griffiths, Elizabeth A.
Wang, Eunice S.
LEUKEMIA RESEARCH, 2018, 75 : 29 - 35
[7] Intensive Chemotherapy Vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience
Vachhani, Pankit
Al Yacoub, Raed
Miller, Austin
Cronin, Tara
Ontiveros, Evelena P.
Thompson, James E.
Griffiths, Elizabeth A.
Wang, Eunice S.
BLOOD, 2017, 130
[8] Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
Karrar, Omer
Iftikhar, Moazah
McCullough, Kristen
Johnson, Isla
Abdelmagid, Maymona
Al-Kali, Aref
Alkhateeb, Hassan
Begna, Kebede
Mangaonkar, Abhishek A.
Saliba, Antoine
Hefazi, Mehrdad
Litzow, Mark R.
Hogan, William J.
Shah, Mithun V.
Patnaik, Mrinal M.
Pardanani, Animesh D.
Badar, Talha
Murthy, Hemant S.
Foran, James M.
Palmer, Jeanne
Sproat, Lisa
Khera, Nandita
Yi, Cecilia Y. Arana
Tefferi, Ayalew
Gangat, Naseema
BLOOD, 2023, 142
[9] Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Agarwal, Suresh
Gopalakrishnan, Sathej
Mensing, Sven
Potluri, Jalaja
Hayslip, John
Friedel, Anna
Menon, Rajeev
Salem, Ahmed Hamed
BLOOD, 2018, 132
[10] Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador, Jorge
Martinez-Cuadron, David
de la Fuente, Adolfo
Rodriguez-Veiga, Rebeca
Serrano, Josefina
Tormo, Mar
Rodriguez-Arboli, Eduardo
Ramos, Fernando
Bernal, Teresa
Lopez-Pavia, Maria
Trigo, Fernanda
Martinez-Sanchez, Maria Pilar
Rodriguez-Gutierrez, Juan-Ignacio
Rodriguez-Medina, Carlos
Gil, Cristina
Belmonte, Daniel Garcia
Vives, Susana
Foncillas, Maria-Angeles
Perez-Encinas, Manuel
Novo, Andres
Recio, Isabel
Rodriguez-Macias, Gabriela
Bergua, Juan Miguel
Noriega, Victor
Lavilla, Esperanza
Roldan-Perez, Alicia
Sanz, Miguel A.
Montesinos, Pau
CANCERS, 2022, 14 (09)

← 1 2 3 4 5 →